Kymera Therapeutics, Inc. (KYMR) News
Track canonical SquawkNews coverage tagged to KYMR, Kymera Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
KYMR - Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
KYMR - Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
EARNINGS | Aug 05, 2026, 11:00 AM UTC
L
KYMR Initiated Hold W/$120.00 PT at Deutsche Bank
KYMR Initiated Hold W/$120.00 PT at Deutsche Bank
EQUITY | Jul 30, 2026, 12:01 PM UTC
H
KYMR Rated Hold
KYMR rated hold with $120 price target
EQUITY | Jul 30, 2026, 11:29 AM UTC
H
Deutsche Bank rates Kymera HOLD
Deutsche Bank initiates Kymera at HOLD
EQUITY | Jul 30, 2026, 10:42 AM UTC
L
KYMR Think Co should be credited value if KT-579 shows healthy volunteer data in 2H26 that demonstrates safe >90% IRF5 degradation @ GUGG
KYMR Think Co should be credited value if KT-579 shows healthy volunteer data in 2H26 that demonstrates safe >90% IRF5 degradation @ GUGG
EQUITY | Jul 28, 2026, 01:27 PM UTC
L
KYMR Maintain Overweight and $140 PT ahead of two key readouts expected later this year @ Piper
KYMR Maintain Overweight and $140 PT ahead of two key readouts expected later this year @ Piper
EQUITY | Jul 16, 2026, 12:25 PM UTC
L
American Express, Biogen upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: JPMorgan upgraded American Express
EQUITY | Jul 13, 2026, 01:43 PM UTC
L
Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing
() -- Nello Mainolfi, Director, Chief Executive Officer, on July 07, 2026, sold 50,000 shares in Kymera Therapeutics (KYMR) for $5,950,000. Following the Form 4 filing with the SEC, Mainolfi has control over a total of 6
REGULATION | Jul 08, 2026, 07:32 AM UTC
L
Kymera Therapeutics shares are trading higher after B of A Securities raised its price target on the stock from $110 to $125.
Kymera Therapeutics shares are trading higher after B of A Securities raised its price target on the stock from $110 to $125.
EQUITY | Jun 30, 2026, 05:08 PM UTC
L
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $110 to $125.
EQUITY | Jun 30, 2026, 02:56 PM UTC
M
B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $117 to $155.
EQUITY | Jun 29, 2026, 02:35 PM UTC
M
KYMR: Canaccord Genuity Raises PT
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics with a Buy and raises the price target from $106 to $129
EQUITY | Jun 26, 2026, 03:07 PM UTC
M
Kymera Completes Enrollment
Kymera Therapeutics completes enrollment in global BROADEN2 Phase 2b trial of KT-621 for atopic dermatitis treatment
EQUITY | Jun 25, 2026, 11:04 AM UTC
M
KYMR Completes Enrollment
Kymera Therapeutics completes enrollment in the Phase 2b BROADEN2 trial of KT-621 in atopic dermatitis with topline data expected by year-end 2026
EQUITY | Jun 25, 2026, 11:00 AM UTC